Your browser version may not work well with NCBI's Web applications. More information here...
1: J Am Coll Cardiol. 2005 Feb 15;45(4):489-92.Click here to read Links
Comment in:
J Am Coll Cardiol. 2005 Aug 16;46(4):737-8; author reply 738-9.
J Am Coll Cardiol. 2005 Feb 15;45(4):496-8.

Association of interatrial shunts and migraine headaches: impact of transcatheter closure.

Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R.

Department of Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.

OBJECTIVES: To examine the relationship between patent foramen ovale (PFO) or atrial septal defect (ASD) with the incidence of migraine headache (MHA) and assess whether closure of the interatrial shunt in patients with MHA would result in improvement of MHA. BACKGROUND: Migraine headache is present in 12% of adults and has been associated with interatrial communications. This study examined the relationship between PFO or ASD with the incidence of MHA and assessed whether closure of the interatrial shunt in patients with MHA would result in improvement of MHA. METHODS: A sample of 89 (66 PFO/23 ASD) adult patients underwent transcatheter closure of an interatrial communication using the CardioSEAL (n = 22), Amplatzer PFO (n = 43), or the Amplatzer ASD (n = 24) device. RESULTS: Before the procedure, MHA was present in 42% of patients (45% of patients with PFO and 30% of patients with ASD). At three months after the procedure, MHA disappeared completely in 75% of patients with MHA and aura and in 31% of patients with MHA without aura. Of the remaining patients, 40% had significant improvement (>or=2 grades by the Migraine Disability Assessment Questionnaire) of MHA. CONCLUSIONS: Transcatheter closure of PFO or ASD results in complete resolution of MHA in 60% of patients (75% of patients with migraine and aura) and improvement in symptoms in 40% of the remaining patients. Interatrial communications may play a role in the etiology of MHA either through paradoxic embolism or humoral factors that escape degradation in bypassing the pulmonary circulation. A randomized trial is needed to determine whether transcatheter closure of interatrial shunts is an effective treatment for MHA.

PMID: 15708691 [PubMed - indexed for MEDLINE]